A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

— Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — — Provides preliminary revenue and gross margin ranges for the second quarter of 2022; amends full-year ...

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

SAN FRANCISCO-- (BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the ...

– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NVTA ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare ...

The genetic testing company has been unprofitable as it spent heavily (but that’s only part of the story). For years I have detested the growth-at-all-costs business models followed by emerging growth ...

SAN FRANCISCO, July 18, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading ...